Novo Nordisk justifies reasoning behind failed GLP-1 Alzheimer's trials

Core Insights - Novo Nordisk launched pivotal trials of its GLP-1 drug semaglutide in Alzheimer's patients in 2020, based on studies conducted in humans, animals, and real-world findings [1] Group 1 - The trials aim to explore the efficacy of semaglutide in treating Alzheimer's disease [1] - The decision to initiate these trials was influenced by promising preliminary data from various studies [1] - A top company executive highlighted the significance of these trials in expanding the therapeutic applications of semaglutide [1]